Less than 10% of individuals that would benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it publishes its inaugural guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to these injectable treatments.
Based on projections, more than two billion will be obese by 2030 if no action is taken.
"The latest guidance affirms that obesity is a chronic disease that can be addressed with comprehensive and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key hurdles to broad access to the treatments that can help people shift substantial weight, explains the body.
GLP-1 Therapy Scarcity
Despite the current best projected outlook, the supply of such drugs might only reach about 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The advice urges countries and companies to increase availability, through strategies like voluntary licensing.
Exclusive production rights on the active ingredient – the main component of a leading brand – is due to expire in several nations in 2026.
How Weight-Loss Jabs Operate
The injections imitate a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so individuals reduce food intake.
People typically start to lose weight after several weeks of commencing the regular doses.
Evidence indicates patients may regain a significant portion within a year of discontinuing the drug, when their typical appetite resume.
Being above a healthy weight elevates your risk for contracting diseases, like diabetes, heart disease, stroke, and some cancers.
Obesity impacts people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
